Jubilant Ingrevia Q2 FY27: Revenue up 24% to ₹1,394 Cr, EBITDA up 51% to ₹221 Cr
Jubilant Ingrevia reported Q2 FY27 revenue of ₹1,394 Cr (up 24% YoY) and EBITDA of ₹221 Cr (up 51% YoY). The company is acquiring a 40% stake in Zettaone Technologies for ₹189 Cr. Specialty Chemicals revenue grew 16% YoY, and Nutrition & Health Solutions revenue increased 50% YoY.
The substantial year-on-year growth in key financial metrics (revenue and EBITDA) and the strategic acquisition of a significant stake in Zettaone Technologies are material developments that are likely to have a significant impact on the company's future performance and market position.
The company reported strong year-on-year growth in revenue and EBITDA, exceeding previous performance metrics and indicating positive business momentum. The strategic acquisition of Zettaone Technologies also signals a forward-looking growth strategy.
Jubilant Ingrevia Limited reported a strong performance for the quarter and half-year ended September 30, 2026. For Q2 FY27, the company's revenue reached ₹1,394 crore, marking a 24% year-on-year increase, driven by improved realizations and stable volumes. EBITDA saw a significant jump of 51% year-on-year to ₹221 crore, the highest in the last three years, with Profit After Tax (PAT) increasing by 60% year-on-year to ₹111 crore.
The company also announced a strategic agreement to acquire a 40% stake in Zettaone Technologies Limited for an investment of ₹189 crore, marking its entry into the electronics design management system space. This acquisition is expected to enable Jubilant Ingrevia to offer an integrated value proposition to customers in the electronics and semiconductor sectors.
Across its business segments, Specialty Chemicals delivered revenue of ₹560 crore, up 16% year-on-year, with EBITDA at ₹140 crore and a margin of 25%. The Nutrition and Health Solutions business reported revenue of ₹270 crore, a 50% year-on-year increase, and EBITDA of ₹39 crore with healthy margins. The Chemical Intermediates segment saw revenue grow by 24% year-on-year to ₹563 crore, with EBITDA rising to ₹64 crore.
Management expressed confidence in sustaining growth momentum, with expectations of continued growth across all three business segments in FY2027. The company reiterated its full-year guidance and anticipates being closer to the upper end of its projected range. Future outlook includes commissioning a new multipurpose plant by year-end to strengthen its CDMO and fine chemicals roadmap. The company also plans to invest ₹400-500 crore annually in capex for new plant facilities.
What to do with a filing like this
Jubilant Ingrevia Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jubilant Ingrevia Limited. Read the original for the full detail.